What if cancer cells could be re-engineered to turn against their own kind?
A new study in Science Translational Medicine, led by researchers at Brigham and Women’s Hospital, leverages the power of gene editing to take a critical step toward using cancer cells to kill cancer. The team reports promising results in preclinical models across multiple types of cancer cells, establishing a potential roadmap toward clinical translation for treating primary, recurrent and metastatic cancer.
“This is just the tip of the iceberg,” said corresponding author Khalid Shah MS, PhD, director of the Center for Stem Cell Therapeutics and Imaging (CSTI) in the BWH Department of Neurosurgery and faculty at Harvard Medical School and Harvard Stem Cell Institute (HSCI). “Cell-based therapies hold tremendous promise for delivering therapeutic agents to tumors and may provide treatment options where standard therapy has failed. With our technique, we show it is possible to reverse-engineer a patient’s own cancer cells and use them to treat cancer. We think this has many implications and could be applicable across all cancer cell types.”
The new approach capitalizes on cancer cells’ self-homing ability – the process in which cancer cells can track the cells of their kind that have spread within the same organ or to other parts of the body. Harnessing this power could overcome drug delivery challenges, helping get therapeutics to tumor sites that may otherwise be difficult to reach.
The team developed and tested two techniques to harness the power of cancer cells. The “off the shelf” technique used pre-engineered tumor cells that would need to be matched to a patient’s HLA phenotype (essentially, a person’s immune fingerprint). The “autologous” approach used CRISPR technology to edit the genome of a patient’s cancer cells and insert therapeutic molecules. These cells could then be transferred back into the patient.
To test both approaches, the team used mouse models of primary and recurrent brain cancer and breast cancer that has spread to the brain. The team saw direct migration of engineered cells to the sites of tumors and found evidence that the engineered cells specifically targeted and killed recurrent and metastatic cancer in the mice. The researchers report that the treatment increased the survival of the mice. Engineered cells were equipped with a “kill switch” that could be activated after treatment – PET imaging showed that this kill switch worked to eliminate the cells.
“Our study demonstrates the therapeutic potential of using engineered tumor cells and their self-homing properties for developing receptor-targeted therapeutics for various cancers,” said Shah.
Learn more: Engineered Cancer Cells Can Fight Primary and Metastatic Cancer
The Latest on: Engineered cancer cells
[google_news title=”” keyword=”engineered cancer cells” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Engineered cancer cells
- New stem cell research may have implications for liver transplantationon May 9, 2024 at 9:20 am
Liver disease, due to viral infections, alcohol abuse, obesity, or cancer, accounts for one in every 25 deaths worldwide. A liver transplant can be life saving for people with end-stage liver disease.
- Turning cancer’s defense against itself using novel CAR-T therapyon May 8, 2024 at 8:30 am
Wang Lab pioneers a CAR T-cell therapy targeting the PD-L1 protein used by cancer cells to evade the immune system.
- Oncolytic Viruses: A Promising New Option in Cancer Treatmenton May 8, 2024 at 7:59 am
As part of its Speaking Out video series, Targeted Oncology spoke with Howard D. Edington, MD, about the benefits of using oncolytic viruses in cancer treatment.
- Pan-cancer analysis uncovers a new class of promising CAR T–cell immunotherapy targetson May 3, 2024 at 10:16 am
Targeting anti-cancer therapy to affect cancer cells but not healthy cells is challenging. For chimeric antigen receptor (CAR) T–cell immunotherapy, where a patient's own immune cells are ...
- Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Proteinon May 1, 2024 at 7:30 pm
Planegg/Martinsried, May 2, 2024.Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell ...
- Asimov Expands Lentivirus Production Portfolio with Cell Line Development Serviceon May 1, 2024 at 5:45 pm
The Producer service offers customers a second option for accessing Asimov's technology for the cell and gene therapy development ...
- Replay wins IND clearance for PRAME T cell cancer therapyon May 1, 2024 at 1:01 am
PRAME TCR/IL-15 NK (SY-307) is an engineered T cell receptor natural killer (TCR-NK ... PRAME is a highly immunogenic antigen that is expressed on lots of different cancer cell types, making it an ...
- Sylvester Cancer adding cellular therapy to its arsenal against metastatic melanomaon April 30, 2024 at 5:00 pm
Patients in South Florida with metastatic melanoma will soon have access to tumor-infiltrating lymphocyte therapy, or TIL. The therapy will be available at Sylvester Comprehensive Cancer Center and ...
- Engineered Peptides Open New Avenue for Immunotherapyon April 21, 2024 at 5:00 pm
The goal of immunotherapy is to bolster the body’s natural ability to identify and destroy cancer cells. Current immune checkpoint inhibitors are antibodies designed to block specific immune signaling ...
via Bing News